Hillhurst’s proprietary GLASS^TM platform enables novel uses of therapeutic gases that, up until now, have been  limited by inhaled delivery.  We’ve developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson’s disease, and acute pain.

We are committed to realizing the full medical potential of therapeutic gases for patients in need. Driven by a sense of urgency to treat debilitating diseases with limited treatment options, Hillhurst is enhancing the way therapeutic gases are delivered, unlocking new applications through the development of novel liquid medicines.